Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Core Insights - Amgen Inc. presented positive findings from the Phase 2 Study of MariTide, an investigational obesity treatment, at the J.P. Morgan Healthcare Conference, indicating strong weight loss maintenance among participants [1][2] Group 1: Study Results - The majority of participants maintained weight loss for an additional 52 weeks on lower doses of MariTide [1] - The second year of treatment was well tolerated, with low incidence of nausea and no new safety signals [2] - MariTide demonstrated up to 20% average weight loss in individuals with obesity without Type 2 diabetes, and up to 17% in those with the condition, significantly outperforming placebo [3] Group 2: Ongoing Research - Amgen is conducting six Phase 3 studies of MariTide across obesity and related conditions, including diabetes, heart disease, and sleep apnea [4] Group 3: Analyst Perspectives - Analysts express that the 52-week data update aligns with previous observations, but there are questions regarding the necessary dose for quarterly maintenance [5] - A differentiated product profile for MariTide compared to existing GLP-1 therapies suggests potential for significant market share and multibillion-dollar peak sales opportunities [6] - Amgen's stock showed a slight increase of 0.46%, reaching $325.80 at the time of publication [6]